BEACON - A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Patients With Recurrent Platinum Resistant High Grade Serous Ovarian Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Acronyms BEACON

04 Jun 2024 Results (n=29) assessing the efficacy of cobimetinib, bevacizumab and atezolizumab in women with platinum resistant high grade serous ovarian cancer were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
04 Aug 2023 Planned End Date changed from 28 Feb 2024 to 30 Jun 2025.
04 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 28 Feb 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com